-
June 17, 2022 Psychedelic Business Spotlight – June 17This week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin...
-
June 16, 2022 The Four Psychedelics ETFs Capturing Investor AttentionDespite an overarching shared thesis, the four psychedelics ETFs differ in philosophy, strategy, execution, and...
-
June 10, 2022 Psychedelic Business Spotlight – June 10This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon;...
-
June 3, 2022 Psychedelic Business Spotlight – June 3This week in psychedelic business news: Cybin moves towards clinical trials; Braxia releases data on...
-
May 28, 2022 Find Your Inner Healing with Psychedelic Therapy | ATMA CEO InterviewIn today's episode of PSYCBiz, James, the Psychedelic Investor, sits down with David Harder, Co-CEO...
-
May 27, 2022 5 Next-Generation Psychedelics Entering Clinical Trials This YearModernized psychedelic medicine is coming, whether you like it or not, so here are five...
-
May 27, 2022 Psychedelic Business Spotlight – May 27This week in psychedelic business news: New patents; another Health Canada SAP Approval; and legal...
-
May 20, 2022 CATALYST Summit: 3 Psychedelic Speakers to Catch This WeekendEven if you can't be there in person, it's not too late to get a...
-
May 20, 2022 Psychedelic Business Spotlight – May 20This week in psychedelic business news: Another psychedelic merger; an Optimi Health acquisition; and good...
-
May 19, 2022 Psychedelic Capitalism Takes a Trip to DavosFrom May 21-26, for the first time, the Davos Forum will feature The House of...
